EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Modified mRNA Treatment Restores Cardiac Function in Desmocollin-2–Deficient Mouse Models of Arrhythmogenic Right Ventricular Cardiomyopathy

Yan Zou, Jing Lu, Zhipeng Lian iD, Jianguo Jia, Juan Shen, Qianhe Li, Jennifer Ming Jen Wong iD, Kejia Jin, Wendi Yan, Xinyue Ren iD, Yang Zhang, Chenxing Huang und 12 weitere

Circulation · 24.06.2025 · 151 (25) · 1780-1796

DOI: 10.1161/circulationaha.124.072340 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation, erschienen am 24.06.2025. Verfasst von Yan Zou und 23 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Cardiology (Y. Zou, Z.L., J.J., Q.L., J.M.J.W., K.J., X.R., Y. Zhang, C.H., Y.X., H.G., J. Lin, J.G., Y.D.), Shanghai Institute of Car…. Hauptthemen laut MEDLINE: Arrhythmogenic Right Ventricular Dysplasia, Desmocollins, RNA, Messenger. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart disease characterized by irregular rhythms and right ventricular dysplasia. Sequence variations in desmosomal protein-encoding genes are linked to ARVC development. Effective treatments for ARVC are lacking. Whereas mRNA-based therapies have shown efficacy in humans, their therapeutic potential for inherited cardiomyopathies remains unclear. METHODS: Whole-exome sequencing identified a novel DSC2 sequence variation causing autosomal recessive ARVC in a Chinese family with consanguineous marriage. Mouse models with Dsc2 sequence variation knock-in and constitutive knock-out were generated and analyzed using echocardiography and histology. Transcriptomic and biochemical analyses were conducted to explore ARVC mechanisms. Dsc2 mRNA delivered by intracardiac or transcoronary injection was assessed as a treatment for ARVC in Dsc2 knock-out mice. In addition, effects of Dsc2 mRNA were examined in a transverse aortic constriction mouse model with noninherited right ventricular systolic dysfunction. RESULTS: Dsc2 -deficient mice exhibited right ventricular dilation and dysfunction, mimicking human disease. Transcriptomic analysis identified Myl7 as the most downregulated gene in the right ventricles of Dsc2 -deficient mice, and its restoration by adeno-associated virus 9 rescued heart function. Dsc2 mRNA delivery, with or without lipid nanoparticle encapsulation, normalized heart size and function in Dsc2 -deficient mice. Reduced DSC2 and MLC2a expression was also noted in patients with noninherited dilated cardiomyopathy and in mice with transverse aortic constriction. A single dose of mRNA provided therapeutic effects lasting 2 to 3 months before declining. CONCLUSIONS: Our study reveals novel mechanisms of ARVC caused by DSC2 loss of function, supported by human and mouse data. Loss of Myl7 contributes to reduced cardiac contractility in ARVC and dilated cardiomyopathy with right ventricular systolic dysfunction. Dsc2 mRNA treatment demonstrated significant therapeutic potential in ARVC and transverse aortic constriction models, providing a basis for future clinical applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arrhythmogenic Right Ventricular DysplasiaDesmocollinsRNA, MessengerAnimalsMiceDisease Models, AnimalMice, KnockoutHumansMaleFemaleGenetic TherapyMyosin Light Chains

Stichwörter der Autor:innen

RNA, messengerarrhythmogenic right ventricular dysplasiacardiomyopathiescardiomyopathy, dilateddesmocollinsfibrosis

Substanzen

DesmocollinsRNA, MessengerMyosin Light ChainsDSC2 protein, human

Autor:innen und Institutionen

  • Departments of Cardiology (Y. Zou, Z.L., J.J., Q.L., J.M.J.W., K.J., X.R., Y. Zhang, C.H., Y.X., H.G., J. Lin, J.G., Y.D.), Shanghai Institute of Cardiovascular Diseases.
  • Shanghai RNACure Biopharma Co, Ltd, Shanghai, China (Y. Zou, J. Lu, H. Yu).
  • BGI-Shenzhen, Shenzhen, China (J.S., H. Yang).
  • National Clinical Research Center for Interventional Medicine, Shanghai, China (J.M.J.W., Y. Zhang, J.G., Y.D.).
  • Oriental Pan-Vascular Devices Innovation College, University of Shanghai for Science and Technology, Shanghai, China (W.Y., Y.D.).
  • Department of Cardiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China (F.H.).

ORCID-Profile: Zhipeng Lian, Jennifer Ming Jen Wong, Xinyue Ren, Huanjie Yang, Jun Li, Yamei Xu, Xialian Xu, Hang Yu, Yi Jin, Jinzhong Lin, Yuxiang Dai

Zitieren

APA

Zou, Y., Lu, J., Lian, Z., Jia, J., Shen, J., Li, Q., Wong, J. M. J., Jin, K., Yan, W., Ren, X., Zhang, Y., Huang, C., Yang, H., Huang, F., Li, J., Zhai, J., Xu, Y., Xu, X., Yu, H., …, & Dai, Y. (2025). Modified mRNA Treatment Restores Cardiac Function in Desmocollin-2–Deficient Mouse Models of Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation, 151(25), 1780-1796. https://doi.org/10.1161/circulationaha.124.072340

Vancouver

Zou Y, Lu J, Lian Z, Jia J, Shen J, Li Q, et al. Modified mRNA Treatment Restores Cardiac Function in Desmocollin-2–Deficient Mouse Models of Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation. 2025;151(25):1780-1796. doi:10.1161/circulationaha.124.072340

BibTeX
@article{Zou2025,
  author = {Zou, Yan and Lu, Jing and Lian, Zhipeng and Jia, Jianguo and Shen, Juan and Li, Qianhe and Wong, Jennifer Ming Jen and Jin, Kejia and Yan, Wendi and Ren, Xinyue and Zhang, Yang and Huang, Chenxing and Yang, Huanjie and Huang, Feng and Li, Jun and Zhai, Junyu and Xu, Yamei and Xu, Xialian and Yu, Hang and Jin, Yi and Gong, Hui and Lin, Jinzhong and Ge, Junbo and Dai, Yuxiang},
  title = {Modified mRNA Treatment Restores Cardiac Function in Desmocollin-2–Deficient Mouse Models of Arrhythmogenic Right Ventricular Cardiomyopathy},
  journal = {Circulation},
  year = {2025},
  volume = {151},
  number = {25},
  pages = {1780--1796},
  doi = {10.1161/circulationaha.124.072340}
}
Kostenlos starten →